financetom
Business
financetom
/
Business
/
Ralph Lauren raises annual revenue forecast on strong apparel demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ralph Lauren raises annual revenue forecast on strong apparel demand
Feb 6, 2025 5:37 AM

(Reuters) - Ralph Lauren ( RL ) raised its annual revenue forecast on Thursday, betting on more younger shoppers picking up its spring collection of dresses, skinny cuffed trousers and floral dinner jackets.

Shares of the apparel maker rose 8% in premarket trading.

Unlike European fashion houses LVMH, Hugo Boss and Kering, Ralph Lauren ( RL ) has enjoyed strong demand as efforts to invest in brands such as Polo and Purple Label helped pull in wealthy shoppers, especially from the younger demographic.

Ralph Lauren ( RL ) has also posted strong sales in China over the past nine quarters, as an e-commerce expansion on the Douyin platform and the opening of full-price stores boosted demand for its clothing.

China accounts for about 8% of the company's total sales.

Demand at Ralph Lauren's ( RL ) direct-to-customer channels also remained robust, driven mainly by full-price sales, while its wholesale business is starting to recover in North America following muted growth for several quarters.

The company now expects 2025 revenue to increase between 6% and 7%, compared with its prior forecast for a 3% to 4% rise.

Its third-quarter sales rose to $2.14 billion from $1.93 billion a year earlier, compared with analysts' estimates of $2.01 billion, according to data compiled by LSEG.

(Reporting by Ananya Mariam Rajesh in Bengaluru; Editing by Devika Syamnath)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Abercrombie & Fitch lifts fourth-quarter sales target on strong holiday demand
Abercrombie & Fitch lifts fourth-quarter sales target on strong holiday demand
Jan 13, 2025
(Reuters) - Abercrombie & Fitch ( ANF ) on Monday raised its annual net sales growth target for the current quarter helped by strong demand for its apparel collections during the holiday shopping season. The company now expects fourth-quarter net sales to grow between 7% and 8%, compared with the prior target of 5% to 7% growth. (Reporting by Juveria...
Africa Oil Raises Stake in Orange Basin Block 3B/4B to 18%, Releases Share Buyback Program Results
Africa Oil Raises Stake in Orange Basin Block 3B/4B to 18%, Releases Share Buyback Program Results
Jan 13, 2025
07:08 AM EST, 01/13/2025 (MT Newswires) -- Africa Oil ( AOIFF ) on Monday said it increased its direct interest in Block 3B/4B offshore South Africa to 18%. The block, operated by TotalEnergies, lies to the southeast and on trend with a number of Orange Basin oil discoveries. The company and its subsidiary Africa Oil SA have completed a transaction...
High Tide up 5.5% in U.S. Pre-market, Acquires Majority Stake in German Wholesaler Purecan
High Tide up 5.5% in U.S. Pre-market, Acquires Majority Stake in German Wholesaler Purecan
Jan 13, 2025
07:13 AM EST, 01/13/2025 (MT Newswires) -- High Tide (HITI.V), up 5.5% in U.S. pre-market trading, on Monday said it will acquire 51% of Purecan, a German pharmaceutical wholesaler, for 4.8 million euros in cash and shares. Purecan holds a license to import medical cannabis into Germany and is preparing to launch a telemedicine portal for medical cannabis patients in...
Regeneron Pharmaceuticals' Trial Shows Adjuvant Libtayo Improved Disease-Free Survival After Surgery in CSCC Patients
Regeneron Pharmaceuticals' Trial Shows Adjuvant Libtayo Improved Disease-Free Survival After Surgery in CSCC Patients
Jan 13, 2025
07:12 AM EST, 01/13/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Monday that the phase 3 C-POST trial showed adjuvant treatment with Libtayo led to a statistically significant and clinically meaningful improvement in the primary endpoint of disease-free survival in patients with high-risk cutaneous squamous cell carcinoma after surgery. Libtayo demonstrated a 68% reduction in the risk of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved